来源:药渡撰文:Pharmadeep编辑:维他命近日,德国默克(Merck KGaA)宣布决定终止与恒瑞医药围绕PARP1抑制剂HRS-1167(默克代号M9466)的全球授权合作。这笔签署于2023年10月、总交易金额最高达14亿欧元的重磅BD协议,在推进不足两年半后戛然而止。此次终止合作,恒瑞不仅无需退还已收到的1.6亿欧元(约合12.3亿元人民币)首付款,还重新获得了HRS-1167的全球...
Source Link来源:药渡撰文:Pharmadeep编辑:维他命近日,德国默克(Merck KGaA)宣布决定终止与恒瑞医药围绕PARP1抑制剂HRS-1167(默克代号M9466)的全球授权合作。这笔签署于2023年10月、总交易金额最高达14亿欧元的重磅BD协议,在推进不足两年半后戛然而止。此次终止合作,恒瑞不仅无需退还已收到的1.6亿欧元(约合12.3亿元人民币)首付款,还重新获得了HRS-1167的全球...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.